摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-amino-6-chloro-5-(dimethylamino)pyrazine-2-carboxylate | 1458-21-5

中文名称
——
中文别名
——
英文名称
methyl 3-amino-6-chloro-5-(dimethylamino)pyrazine-2-carboxylate
英文别名
——
methyl 3-amino-6-chloro-5-(dimethylamino)pyrazine-2-carboxylate化学式
CAS
1458-21-5
化学式
C8H11ClN4O2
mdl
——
分子量
230.654
InChiKey
CIJAOZNANCPBRB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    81.3
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 3-amino-6-chloro-5-(dimethylamino)pyrazine-2-carboxylate 在 palladium on activated charcoal sodium hydroxide氢溴酸氢气 、 sodium nitrite 作用下, 以 四氢呋喃乙醇溶剂黄146 为溶剂, 反应 48.5h, 生成 6-氯-5-二甲氨基-吡嗪-2-羧酸
    参考文献:
    名称:
    Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands
    摘要:
    A series of protease inhibitors bearing constrained unnatural amino acids at the P2-position and novel heterocycles at the P3-position of compound 1 (Ro 31-8959) were synthesized, and their in vitro enzyme inhibitory and antiviral activities were evaluated. Replacement of P2-asparagine of compound 1 with (2S,3'R)-tetrahydrofuranylglycine resulted in improvement in enzyme inhibitory as well as antiviral potencies (compound 23). Interestingly, incorporation of (2S,3'S)-tetrahydrofuranylglycine at the P2-position proved to be less effective. The resulting compound 24 was 100-fold less potent than the 2S,3R-isomer (compound 23). This stereochemical preference indicated a hydrogen-bonding interaction between the tetrahydrofuranyl oxygen and the residues of the S2-region of the enzyme active site. Furthermore, replacement of P3-quinolinoyl ligand of 1 with various novel heterocycles resulted in potent inhibitors of HIV proteases. Of particular interest, compound 2 with (2S,3'R)-tetrahydrofuranylglycine at P2 and pyrazine derivative at P3 is one of the most potent inhibitors of HIV-1 (IC50 value 0.07 nM) and HIV-2 (IC50 value 0.18 nM) proteases. Another important result in this series is the identification of compound 27 in which the P2-P3-amide carbonyl has been removed. The resulting compound 27 has exhibited improvement in antiviral potency while retaining the enzyme inhibitory potency similar to compound 1.
    DOI:
    10.1021/jm00068a006
  • 作为产物:
    描述:
    二甲胺3-氨基-5,6-二氯-2-吡嗪羧酸甲脂N,N-二异丙基乙胺 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 16.0h, 以83%的产率得到methyl 3-amino-6-chloro-5-(dimethylamino)pyrazine-2-carboxylate
    参考文献:
    名称:
    使用基于亚胺的动态组合化学进行模板指导的RNA配体选择。
    摘要:
    这项研究建立了基于亚胺的动态组合化学发现RNA靶标的非共价配体的适用性。我们阐明了芳基胺反应性的基础性质,并证明了基于阿米洛利的动态库中目标导向的紧密结合剂的扩增。
    DOI:
    10.1039/d0cc00266f
点击查看最新优质反应信息

文献信息

  • Amiloride as a new RNA-binding scaffold with activity against HIV-1 TAR
    作者:Neeraj N. Patwardhan、Laura R. Ganser、Gary J. Kapral、Christopher S. Eubanks、Janghyun Lee、Bharathwaj Sathyamoorthy、Hashim M. Al-Hashimi、Amanda E. Hargrove
    DOI:10.1039/c6md00729e
    日期:——
    dimethylamiloride from a weak TAR ligand to one of the tightest binding selective TAR ligands reported to date through a novel combination of synthetic methods and analytical techniques. We expect these methods to allow for rapid library expansion and tuning of the amiloride scaffold for a range of RNA targets and for SOFAST NMR to allow unprecedented evaluation of small molecule:RNA interactions.
    RNA靶向支架的多样化为寻找治疗相关RNA(例如HIV-1 TAR)的选择性配体提供了广阔的前景。我们在此报告了阿米洛利作为一种新型的RNA结合支架,以及合成的C(5)-和C(6)-多样化途径的合成途径的建立。在C(5)-和C(6)位置的迭代修饰产生衍生物24,在肽置换试验中,其活性比母体二甲基阿米洛利提高了100倍。使用2D SOFAST- [ 1 H- 13C] HMQC NMR方法,可以轻松快速地评估所有文库成员的结合模式。化学信息学分析揭示了选择性配体和非选择性配体之间的明显差异。在这项研究中,我们通过合成方法和分析技术的新颖结合,将二甲基阿米洛利从弱的TAR配体演化为迄今为止报道的结合最紧密的选择性TAR配体之一。我们希望这些方法能够快速扩增文库并调整阿米洛利支架的RNA靶标范围,并对SOFAST NMR进行前所未有的小分子与RNA相互作用的评估。
  • Pyrazinecarboxamides and processes for preparing same
    申请人:Merck & Co., Inc.
    公开号:US04085211A1
    公开(公告)日:1978-04-18
    The case involves novel pyrazinecarboxamides and processes for preparing same. The pyrazinecarboxamides are excellent eukalemic agents possessing diuretic and natriuretic properties.
    本案涉及新型吡嗪羧酰胺及其制备方法。这些吡嗪羧酰胺是优秀的利尿剂和利尿剂。
  • US4085211A
    申请人:——
    公开号:US4085211A
    公开(公告)日:1978-04-18
查看更多